RYTM - Rhythm Pharmaceuticals - Stock & Dividends

Rhythm Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, is dedicated to developing innovative treatments for rare neuroendocrine diseases that have a significant impact on patients' lives.

The company's lead product candidate, IMCIVREE (setmelanotide), is a melanocortin-4 receptor agonist that has shown promising results in treating various genetic obesity disorders, including pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. IMCIVREE is currently in Phase 3 clinical trials for treating a range of MC4R disorders, including POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, and MC4 receptor deficiency obesity.

Rhythm Pharmaceuticals has established strategic partnerships with leading companies, including LG Chem, Ltd, Ipsen Pharma S.A.S, Camurus, and RareStone Group Ltd, to advance its pipeline and expand its global reach. The company's commitment to collaboration and innovation has enabled it to accelerate the development of its product candidates and improve patient outcomes.

Founded in 2008, Rhythm Pharmaceuticals is headquartered in Boston, Massachusetts, and has undergone significant growth and transformation, including a name change from Rhythm Metabolic, Inc to Rhythm Pharmaceuticals, Inc in 2015. Today, the company is a leading player in the rare disease space, dedicated to making a meaningful difference in the lives of patients and their families.

For more information about Rhythm Pharmaceuticals and its mission to transform the treatment of rare neuroendocrine diseases, please visit https://rhythmtx.com.